TMCnet News
22nd Century to Participate in September and October 2021 Investor ConferencesBUFFALO, N.Y., Sept. 27, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology and intellectual property company focused on improving health and wellness through plant science, today announced that the Company will participate in the following virtual investor conferences during the months of September and October 2021:
During his presentations, James A. Mish, chief executive officer of 22nd Century Group, will highlight the Company’s business development, commercialization, and value creation efforts across its three high-value plant-based franchises. He will discuss plans for commercializing VLN® reduced nicotine content cigarettes in the U.S. and international markets, expectations for monetizing proprietary hemp/cannabis plant lines and IP by the end of this year, and the Company’s development plans following its recently announced entry into the specialty hops market. Institutional investors and those invited to attend these virtual cnference events may request one-on-one meetings with representatives of the Company, where offered, through the respective conference hosts or by contacting 22nd Century Group’s investor relations team via [email protected]. 22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology and intellectual property company focused on improving health and wellness through plant science. 22nd Century uses modern plant breeding technologies, gene-editing, and molecular breeding to deliver value to its customers in the life science and consumer products industries by creating new, proprietary tobacco, hemp/cannabis and hop plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits. 22nd Century was founded to build intellectual property related to nicotine biosynthesis in the tobacco plant and to commercialize its proprietary reduced nicotine content (RNC) tobacco plants, which have become the cornerstone of FDA’s Comprehensive Plan to address the enormous amount of death and disease caused by addiction to smoking. The Company has also begun to leverage its plant science expertise and existing partnerships to create and commercialize new, proprietary hemp/cannabis and hop plants to optimize their genetics and create valuable new intellectual property. Learn more at xxiicentury.com, on Twitter @_xxiicentury, and on LinkedIn. Cautionary Note Regarding Forward-Looking Statements Investor Relations & Media Contact: |